Metabolic drugs

56 drugs with cited findings from FDA review packages and EMA assessment reports. Every figure on every page cites its source document and page.

By condition

Type 2 diabetes (20)Obesity & weight management (6)Type 1 diabetes (10)

By drug class

SGLT2 inhibitors (16)GLP-1 receptor agonists (13)DPP-4 inhibitors (12)Insulins (8)

Endpoints & rating scales explained

HbA1c (glycated hemoglobin)Body weight reduction Fasting plasma glucose

Invokana

Johnson & Johnson · 3972 cited findings

Mounjaro

Eli Lilly and Company · 3299 cited findings

ertugliflozin

Merck & Co., Inc. · 3273 cited findings

Victoza

NOVO NORDISK INC · 3204 cited findings

Jardiance

Boehringer Ingelheim · 3163 cited findings

Wegovy

NOVO · 3136 cited findings

Farxiga

AstraZeneca PLC · 3069 cited findings

dapagliflozin

AstraZeneca PLC · 2783 cited findings

Rybelsus

NOVO · 2266 cited findings

Glyxambi

Boehringer Ingelheim · 2189 cited findings

Tresiba

NOVO · 2078 cited findings

Ozempic

NOVO · 2042 cited findings

Saxenda

Novo Nordisk A S · 1994 cited findings

Zepbound

Eli Lilly and Company · 1766 cited findings

Imcivree

Rhythm B V · 1621 cited findings

semaglutide

Novo Nordisk A S · 1501 cited findings

Trulicity

Eli Lilly and Company · 1474 cited findings

Ryzodeg

Novo Nordisk A S · 1416 cited findings

linagliptin

Boehringer Ingelheim · 1254 cited findings

Xultophy

Novo Nordisk A S · 1186 cited findings

Steglatro

Merck & Co., Inc. · 1185 cited findings

Forxiga

AstraZeneca PLC · 1142 cited findings

Tzield

PROVENTION BIO INC · 1106 cited findings

Kyinsu

Novo Nordisk A S · 1105 cited findings

Lyumjev

Eli Lilly and Company · 1091 cited findings

Awiqli

Novo Nordisk A S · 1067 cited findings

Synjardy

Boehringer Ingelheim · 1015 cited findings

Jentadueto

Boehringer Ingelheim · 936 cited findings

Kayshild

Novo Nordisk A S · 927 cited findings

Vipdomet

Takeda Pharmaceutical Company Limited · 925 cited findings

Mysimba

Orexigen · 922 cited findings

Steglujan

Merck & Co., Inc. · 901 cited findings

Teizeild

Sanofi · 821 cited findings

Vokanamet

Johnson & Johnson · 816 cited findings

Suliqua

Sanofi · 797 cited findings

Vipidia

Takeda Pharmaceutical Company Limited · 788 cited findings

Incresync

Takeda Pharmaceutical Company Limited · 658 cited findings

Xigduo

AstraZeneca PLC · 646 cited findings

BYDUREON

AstraZeneca PLC · 566 cited findings

Januvia

MSD · 552 cited findings

Fiasp

NOVO · 532 cited findings

Komboglyze

AstraZeneca PLC · 443 cited findings

Qtern

Astra Zeneca · 372 cited findings

Levemir

NOVO NORDISK INC · 366 cited findings

faster aspart

Novo Nordisk A S · 219 cited findings

LANTUS

Sanofi · 208 cited findings

Metformin

Takeda Pharmaceutical Company Limited · 197 cited findings

Apidra

Sanofi · 177 cited findings

Amglidia

Ammtek · 173 cited findings

Humalog Mix 50/50

Eli Lilly and Company · 133 cited findings

Xigduo XR

AstraZeneca PLC · 85 cited findings

Ristfor

Merck & Co., Inc. · 79 cited findings

Soliqua 100/33

Sanofi · 79 cited findings

Ristaben

Merck & Co., Inc. · 75 cited findings

Edistride

AstraZeneca PLC · 35 cited findings

Ebymect

AstraZeneca PLC · 33 cited findings

Educational reference only — not medical or investment advice.